TL;DR
This study introduces a novel approach to Alzheimer's Disease (AD) risk prediction by creating polygenic risk scores (PRS) based on biological pathways. They found that pathway-based PRS are specifically associated with the Aβ/Tau proteinopathy subtype of AD, suggesting a more nuanced understanding of AD genetic architecture.
What Problem Does This Paper Address?
Alzheimer's Disease (AD) is a complex neurodegenerative disorder with a significant genetic component. While traditional polygenic risk scores (PRS) aggregate genetic variants associated with AD, they often treat all variants equally, potentially masking specific biological mechanisms. Furthermore, AD is increasingly understood to be heterogeneous, with different proteinopathies (accumulation of misfolded proteins like amyloid-beta, tau, and alpha-synuclein) contributing to the disease. This paper aims to bridge this gap by developing pathway-specific PRS to better understand the genetic underpinnings of different AD proteinopathy subtypes.
Methods
The researchers constructed biological pathway-based polygenic risk scores (PRS) by leveraging Gene Ontology (GO) terms. They started with a large set of single nucleotide variants (SNVs) from AD genome-wide association study (GWAS) summary statistics. These SNVs were filtered based on linkage disequilibrium (r² = 0.1) and physical distance to create independent sets of variants for each GO term. They then used PRSice-2 to calculate PRS for each biological pathway. These pathway-based PRS were then associated with three latent proteinopathy endophenotype scores (TDP-43, Aβ/Tau, and α-synuclein related neuropathology) derived from the National Alzheimer's Coordinating Center (NACC) neuropathology data. Statistical associations were adjusted for age at death, sex, principal components of ancestry, and the other two non-outcome latent scores. P-values were corrected using the Bonferroni method.
Datasets
- National Alzheimer's Coordinating Center (NACC) neuropathology data: Used to derive three continuous latent proteinopathy endophenotype scores (TDP-43, Aβ/Tau, and α-synuclein related neuropathology).
- Alzheimer's Disease Genetics Consortium (ADGC) genotype data: Genotype data linked to the NACC participants.
- TOPMed Imputation Server: Used for imputing ADGC genotype data.
- GWAS Catalog (specifically, summary statistics from Bellenguez et al.): Provided the AD summary statistics for PRS calculation.
Key Insights and Ideas
- Pathway-level genetics matters: This study highlights that aggregating genetic variants based on biological pathways can reveal associations that might be missed by traditional, non-pathway-based PRS.
- AD heterogeneity reflected in genetics: The findings suggest that the genetic architecture of AD might be more specific to certain proteinopathy subtypes than previously appreciated.
- Aβ/Tau pathway is genetically distinct: The strong association of pathway-based PRS with the Aβ/Tau proteinopathy score indicates a particularly strong genetic influence on this specific pathological hallmark of AD.
Key Results
The study identified that biological pathway-based AD PRS were significantly associated with the Aβ/Tau pathway-related latent proteinopathy score. Specifically, PRS derived from GO terms related to "membrane" cellular component and "protein binding" molecular function showed strong associations with the Aβ/Tau pathology score, with corrected p-values of 1.7 × 10⁻⁶ and 0.00011, respectively. Importantly, no significant associations were found between biological pathway-based AD PRS and the TDP-43 or α-synuclein pathology-related latent scores.
Limitations and Future Work
The authors acknowledge that the biological pathway-based PRS were only associated with the Aβ/Tau proteinopathy score. They propose to explore PRS for other diseases that may be related to AD etiology, such as Parkinson's disease (linked to α-synuclein pathology), amyotrophic lateral sclerosis (ASL) (linked to TDP-43 aggregation), cardiovascular diseases, cardiovascular risk factors, and psychiatric diseases. This suggests a future direction of investigating cross-disease genetic pathways and further refining the understanding of AD's complex genetic landscape.
Summary updated